Home/Filings/4/0001209191-23-024058
4//SEC Filing

MCDADE MARK 4

Accession 0001209191-23-024058

CIK 0001788028other

Filed

Apr 10, 8:00 PM ET

Accepted

Apr 11, 7:55 PM ET

Size

9.8 KB

Accession

0001209191-23-024058

Insider Transaction Report

Form 4
Period: 2023-01-27
Transactions
  • Purchase

    Voting Common Stock

    2023-01-27$1.50/sh+2,666,666$3,999,9998,519,648 total
MCDADE MARK
10% Owner
Transactions
  • Purchase

    Voting Common Stock

    2023-01-27$1.50/sh+2,666,666$3,999,9998,519,648 total
Transactions
  • Purchase

    Voting Common Stock

    2023-01-27$1.50/sh+2,666,666$3,999,9998,519,648 total
Transactions
  • Purchase

    Voting Common Stock

    2023-01-27$1.50/sh+2,666,666$3,999,9998,519,648 total
Footnotes (1)
  • [F1]The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Issuer

Jasper Therapeutics, Inc.

CIK 0001788028

Entity typeother

Related Parties

1
  • filerCIK 0001242126

Filing Metadata

Form type
4
Filed
Apr 10, 8:00 PM ET
Accepted
Apr 11, 7:55 PM ET
Size
9.8 KB